In 3 Pa. Rulings, Pharma Loses A Little But Gains A Lot

Law360, New York (August 31, 2010, 1:38 PM EDT) -- In a trio of recent Pennsylvania Superior Court decisions involving the diet drug Redux, plaintiffs lawyers may have gained a new cause of action against pharmaceutical manufacturers, but not before the reaffirmance of the learned intermediary defense and the rejection of a plaintiff's unique challenge to that defense.

In Lance v. Wyeth,[1] considering an issue of first impression, the court held a claim for negligent design defect is a proper cause of action in Pennsylvania in a pharmaceutical products liability case. In Lance, the plaintiff's decedent...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.